|
|
|
|
FOCUS ON TRANSLATIONAL RESEARCH |
|
|
|
By Carlos Bañado, CEO, ARScience Bio | By promoting cell expansion, survival, and functionality, interleukins help optimize therapeutic outcomes in cancer immunotherapy and regenerative medicine. Let’s look closer and compare ex vivo and in vivo approaches. | |
|
|
|
| How To Evaluate And Compare Real-Time PCR Reactions | Application Note | Applied Biosystems by Thermo Fisher Scientific, qPCR | Learn about the key factors that influence qPCR reaction performance and provides guidelines for evaluating and comparing reactions run under varying conditions to ensure reliable data interpretation. |
|
|
| Oligonucleotides: Where We Are And Where We Would Like To Go | White Paper | By Troy Voelker, Ph.D., Aliri Bioanalysis | Explore the current knowledge and future directions of the bioanalysis of oligonucleotides. Review the pros and cons of various analytical platforms, methods of extraction, and approaches for these molecules. |
|
|
|
| Expanding Translational Research Concepts | White Paper | Danaher Life Sciences | The biopharma industry leverages Genedata Profiler to integrate, curate, and analyze diverse R&D data, enabling collaborative, compliant, and AI-driven translational research to optimize drug development. |
|
|
|
|
|
| Webinar: Evolving Gene Editing for Rare Disease Drug Development | Danaher is partnering with leading academic and clinical research institutes focused on the development of a novel platform approach to gene editing aimed at accelerating the delivery of therapies and creating economies of scale to treat ultra-orphan conditions. We will explore how to create scalable models for efficient manufacturing and broader patient access and formulate regulatory and clinical strategies to address rare disease challenges. Learn more. |
|
|
TRANSLATIONAL RESEARCH SOLUTIONS |
|
|
|
|
|
| Advancing the Future of Cell & Gene Therapy | This 11-12 November, Cell 2025 unites 1,000+ leading experts across the CGT value chain to solve key challenges, from scalable bioprocessing and regulatory hurdles to accelerating development timelines. Gain practical strategies across cell culture, therapy development, and CGT manufacturing, and hear from world-renowned leaders Bobby Gaspar (CEO, Orchard Therapeutics), Christof Von Kalle, (Director & BIH Chair, Research Clinic Luxemburg), and Dame Molly Stevens (University of Oxford). Register Now |
|
|
| Connect With Cell & Gene: |
|
|
|
